Biogen (BIIB) PT Raised to $309 at Baird on Additional Sola Details
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Biogen Presents Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimer’s Disease Meeting
December 8, 2016 6:16 PM ESTData Includes Analyses of Phase 1b Titration Cohort and Long-Term Extension Cohort
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen (NASDAQ: BIIB) announced it will present new data from the Phase 1b (PRIME) study of aducanumab, its investigational treatment for early Alzheimers disease (AD), today at the 9th Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego.... More
